SMALL MOLECULE INHIBITORS FOR EARLY DIAGNOSIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN CANCERS AND NEURODEGENERATIVE DISEASES
申请人:Venkatesh Chelvam
公开号:US20200164075A1
公开(公告)日:2020-05-28
Accordingly, embodiments herein disclose a compound and method of small molecule inhibitors or ligands for diagnosis and treatment of cancers such as prostate, brain, breast, etc., and neurodegenerative diseases. A new class of PSMA inhibitors called as aminoacetamide, 1, has been designed by extensive in silico studies. A simple, mild and high yielding synthetic methodology is developed for 1 and shown to have high affinity for PSMA protein. Fluorescent conjugates 22 and 25 derived from 1 show selective uptake in prostate cancer cell lines and can be used for surgical removal of tumors during intra-operative surgery. Conjugates 31 and 34 for tagging 99mTc radioisotope were synthesized. Macrocyclic chelating cores such as DOTA, NOTA or prosthetic groups can be introduced to tag radionuclides 68Ga, 64Cu, 18F and 177Lu for diagnosis and treatment of PCa, incurable mCRPC and neurodegenerative diseases such as ALS, schizophrenia and neuropathic pain that over-express PSMA protein.
因此,本文揭示了一种化合物和小分子抑制剂或配体的方法,用于诊断和治疗前列腺、脑部、乳腺等癌症,以及神经退行性疾病。通过广泛的计算机辅助设计研究,设计了一类新型PSMA抑制剂,称为氨基乙酰胺1。开发了一种简单、温和且高产率的合成方法用于合成1,并显示其对PSMA蛋白具有高亲和力。从1衍生的荧光偶联物22和25显示出在前列腺癌细胞系中的选择性摄取,并可用于术中手术切除肿瘤。合成了用于标记99mTc放射性同位素的偶联物31和34。可以引入类似DOTA、NOTA或假体基团的大环螯合核心,以标记放射性同位素68Ga、64Cu、18F和177Lu,用于诊断和治疗前列腺癌、不可治愈的mCRPC和过度表达PSMA蛋白的神经退行性疾病,如ALS、精神分裂症和神经病性疼痛。